Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Day One Biopharmaceuticals, Inc.
CEO
Dr. Jeremy Bender M.B.A., Ph.D.
Employees
155
Industry
Biotechnology
Sector
Healthcare
Market cap
$1B
Company details
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Revenue
CoG
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$101.95M
Cost of goods (CoG)
-$2.30M
Gross profit (GP)
$99.66M
Operating expense (OE)
-$311.11M
Research and development (R&D)
-$203.23M
General and administrative (G&A)
-$107.88M
Operating income (OI)
-$211.46M
Other income expense (OIE)
-$127.83M
Pretax income (PI)
-$83.62M
Tax (TAX)
-$670,000.00
Net income (NI)
-$84.29M
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.87
Margin profit
-82.68%
52 week low
$12.03
52 week high
$17.690001
50-day simple moving average
$14.37
200-day simple moving average
$14.15
Percent held by insiders
17.01%
Percent held by institutions
93.22%
Dividend yield
0.00%
